News

Read our latest news, and find more about us and our portfolio companies.

2017/12/12
aveni® S.A. Extends Copper Interconnects to 5nm and Below for BEOL Integration Using Innovative Electroplating Chemistry

aveni S.A., developer and manufacturer of market-disrupting wet deposition technologies and chemistries for 2D interconnects and 3D through silicon via packaging, today announced it has obtained results that strongly support the continued use of copper in the back end of line (BEOL) for advanced interconnects, at and beyond the 5nm technology node.

2017/12/11
STORM Therapeutics Announces Appointments to Scientific Advisory Board

STORM Therapeutics, the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of both Professor Mark Dawson and Dr Paul Leeson to the Scientific Advisory Board.

2017/12/06
Synaffix Launches toxSYN™, a New Platform of ADC Payloads

AMSTERDAM, NETHERLANDS – December 6, 2017 – Synaffix BV, a biotechnology company that has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates (ADCs), today announced the launch of a new platform of highly potent cytotoxic ADC payloads that will be integrated into its existing ADC platform. With this expansion, Synaffix becomes a one-stop provider for technologies required to rapidly translate antibodies into proprietary ADC products.

2017/12/04
Akili Achieves Primary Efficacy Endpoint in Pediatric ADHD Pivotal Trial

Company Completes Large Multi-Center, Randomized, Controlled Study of Novel Digital Medicine and Plans Regulatory Filing

2017/11/29
Synaffix Commands IP Space of Glycan-Conjugated ADCs Through Major Expansion of Granted Patent Portfolio

Synaffix BV, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), today announced the granting of a key patent that encompasses the entire GlycoConnect™ process.

2017/11/28
iOnctura Announces Appointment of Leading International Scientific Advisory Board

iOnctura SA, a recently founded late stage preclinical immuno-oncology company, announced today the formation of an international Scientific Advisory Board (SAB).

2017/11/27
Biolinq Completes $10M Series A Financing

Biolinq today announced the close of a $10M Series A financing led by M Ventures, in collaboration with Hikma Ventures. Biolinq is a digital health company with a unique, wirelessly-enabled biosensor patch that is capable of continuously monitoring multiple biomarkers.

2017/11/27
STORM THERAPEUTICS ANNOUNCES PUBLICATION IN NATURE ON RNA EPIGENETICS BY FOUNDER PROFESSOR TONY KOUZARIDES

New Drug Target Discovered For Acute Myeloid Leukaemia STORM Therapeutics, the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the publication of data in the internationally renowned scientific journal Nature linking an essential RNA-modifying enzyme to acute myeloid leukaemia (AML)

2017/11/13
The IQVIA Institute for Human Data Science's Latest Report Names Medisafe as The Top Free & Publicly Available App for Medication Management

Designation Champions Medisafe's Medication Management Platform as A Best-in Class Solution for Managing the Critical Problem of Patient Non-adherence

2017/11/06
STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research

STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Professor Paul Workman to its Board. This appointment continues STORM’s evolution of its management and advisory networks as it fulfils its ambition to become the leading therapeutics company in RNA epigenetic modulation.

2017/11/02
Two Global Leaders in Technology and Healthcare Join List of Venture Capitalists Investing in Wiliot to Scale IoT with Battery-Free Bluetooth

Qualcomm Ventures and M Ventures Join Investor Group Including Grove Ventures Partners, Norwest Venture Partners and 83North Venture Capital

2017/10/26
Taking RNA epigenetics by Storm

Storm is tapping the nascent field of RNA epigenetics for cancer

2017/10/24
aveni® S.A. Raises €8.9M ($10.5M) in Series B Financing from M Ventures and Existing Investors to Commercialize its Innovative Metallization Technologies

PARIS, France – October 24, 2017 aveni S.A., developer and manufacturer of market disrupting wet deposition technologies and chemistries for 2D interconnects and 3D TSV packaging, today announced it has completed a €8.9M ($10.5M) capital raise from M Ventures, the corporate venture arm of Merck, along with existing investors.

2017/10/23
Peratech raises $12.4 million (£9.2 million) in financing from M Ventures, Arie Capital and existing investors to scale up technology solutions

Peratech, a world leader in 3D force-sensing technologies, announced it has subscribed $12.4 million (£9.2 million) to the round of funding, led by M Ventures the venture capital wing of Merck, along with Arie Capital and existing investors.

2017/10/11
ADC Therapeutics Triggers Second Target-Specific License to Synaffix ADC Platform under Existing Agreement

Synaffix BV announced today that ADC Therapeutics has triggered a second target-specific license under their Commercial License Agreement dated October 2016, to develop an antibody-drug conjugate (ADC) using Synaffix’s proprietary site-specific antibody-drug conjugation technology. As part of the original agreement, ADC Therapeutics retains an option to take a limited number of additional singletarget licenses for their potential future programs.

2017/10/10
FORENDO PHARMA NOMINATES WORLD CLASS SCIENTIFIC ADVISORY BOARD AND ELECTS PROFESSOR LINDA GIUDICE AS THE CHAIRPERSON

Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, announces the nomination of its Scientific Advisory Board today. Forendo is developing tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometrial tissues. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels as demonstrated in preclinical models. This selective activity is expected to allow safer long-term treatment of this chronic disease without harmful symptoms of estrogen deficiency.

2017/09/24
Synaffix Awarded "Runner Up" Postion for Best Platform ADc Technology

World ADC is pleased to announce the finalists in the 4th Annual World ADC Awards. The World ADC Awards showcase the innovation, leadership and devotion shown by the best companies, teams and individuals in the industry. Across 9 categories the Awards will recognise the extraordinary endeavours, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.

2017/09/15
Artios Pharma wins Life Science Young Company of the Year and UK Private Finance Raise at the Biotech and Money Annual Awards 2017

Cambridge, UK, 15 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, is pleased to announce that it has won the “Life Science Young Company of the Year” and “UK Private Finance Raise of the Year” awards at last night’s Biotech and Money Awards 2017.

2017/09/13
VAXIMM Receives Orphan Designation for the European Union and the US for Oral T-cell Immunotherapy VXM01 to Treat Glioma

VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company's lead product candidate, VXM01, has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioma, a difficult-to-treat form of brain cancer. Orphan designation is designed to encourage the development of drugs to treat rare diseases and conditions and provides companies with certain incentives, including periods of market exclusivity upon approval, as well as user fee reductions or exemptions. The designation by the European Commission is for the treatment of glioma and by the US FDA for the treatment of malignant glioma.

2017/09/12
M Ventures participates in DNA Script' Successful Series A Fundraising of €11 M to Advance Development of its DNA Synthesis Technology

Paris, September 12th, 2017. Synthetic DNA manufacturer DNA Script has today announced a Series A fundraising of 11 million euros ($13 million) led by Illumina Ventures, with additional investments from M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, plus existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners.

2017/09/04
Artios Pharma appoints Dr Graeme Smith as Chief Scientific Officer

Artios Pharma appoints Dr Graeme Smith as Chief Scientific Officer Co-inventor of Lynparza™ joins Artios

2017/08/23
Macrophage Pharma Limited Extends Series A Round to Include New Investor M Ventures

M Ventures Joins Investment Syndicate and the Board of Macrophage

2017/08/18
ALCAN, a German Smart Antenna Start-up, Raises EUR 7.5 million to Manufacture Flat Panel Phased Array Antennas

A consortium of leading global corporations has invested in ALCAN’s market-leading smart antenna technology to support the roll-out of the company’s first flat panel phased array antennas.

2017/07/27
Storm Therapeutics expands collaboration with Evotec on Storm's RNA Epigenetics Platform

**STORM Therapeutics and Evotec to exploit RNA modulating enzymes for novel epigenetic drug discovery**

2017/07/10
Parkinson’s disease: Prexton announces initiation of phase II clinical testing

Study will evaluate first-in class treatment in six European countries

2017/06/29
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting

- Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART - Non-clinical results of OBE022 for PTL demonstrate both monotherapy/combination potential

2017/06/20
M Ventures Creates New Immuno-Oncology Company iOnctura

Darmstadt, Germany, June 20, 2017 – Merck, a leading science and technology company, today announced its corporate venture arm M Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). CRT is the commercial arm of Cancer Research UK, London, UK. M Ventures will manage the investment and will be represented on iOnctura’s board of directors.

2017/06/08
Artios announces formation of world-leading Scientific Advisory Board

Cambridge, UK, 8 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company focussed on developing innovative new treatments for cancer, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts from across Europe and the United States, in the fields of DDR, DNA genetics and drug discovery. Dr Simon Boulton, VP Scientific Strategy at Artios, will serve as Chairman.

2017/06/07
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy

ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced the completion of a Phase 1 clinical trial aimed at evaluating the PK/PD relationship of OBE2109 combined with different doses of add-back therapy.

2017/06/04
F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology

F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and technology company, for the development and commercialisation of five bispecific immuno-oncology antibodies (mAb2 TM).

2017/05/31
M Ventures leads $11M round in solid tumor startup Inthera Bioscience

M Ventures has led a $10.8 million (€9.6 million) investment in Inthera Bioscience. The series A sets the Swiss biotech up to wrap up preclinical development of a lead candidate against cancers associated with human papillomavirus (HPV).

2017/05/16
Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States

exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that a key patent covering its HydraSpace™ spacer technology has been granted by the United States Patent and Trademark Office (US 9,636,421 B2).

2017/05/11
ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017

Geneva, Switzerland and Boston, MA - May 11, 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will report financial results for the first quarter ended March 31, 2017 on Thursday, May 18, 2017.

2017/05/09
VAXIMM Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies

Basel (Switzerland) and Mannheim (Germany), May 9, 2017 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company which in the US and Canada operates as EMD Serono, and Pfizer Inc. (NYSE: PFE) to evaluate avelumab*, a human anti-PD-L1 antibody, in combination with VAXIMM’s VXM01. VXM01 is an investigational oral T-cell immunotherapy designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly. Under the terms of the agreement, VAXIMM will be responsible for conducting two open-label Phase I/II trials – one in glioblastoma and one in metastatic colorectal cancer.

2017/03/30
VAXIMM to present preclinical data on three novel oral T-cell immunotherapies at AACR Annual Meeting 2017

Basel (Switzerland) and Mannheim (Germany), March 30, 2017 - VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that preclinical data for three of its programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 being held in Washington, DC, USA, April 1-5.

2017/03/29
Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.

2017/03/24
ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

2017/03/17
Pogue's quest for the best pill-reminder app

I’ll admit it: Apps that remind you to take your pills are not as sexy as, say, folding laptops or MP3 toothbrushes. But they’re important. Every year an estimated 125,000 Americans die from taking their pills incorrectly, according to a 2012 study from the Annals of Internal Medicine.

2017/03/17
ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor

- OBE022 is ObsEva's potential first-in-class, oral and selective PGF2alpha receptor antagonist -

2017/03/07
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART

- IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer as part of assisted reproductive technology (ART) -

2017/03/01
Medisafe Raises $14.5M in Funding to Support Rapid Growth and Global Expansion

LONDON and BOSTON, March 1, 2017 — Medisafe®, the leading personalized medication management platform with over three and a half million patient and caregiver registered users, announced today that it has raised a $14.5M Series B funding round led by Octopus Ventures, and joined by M Ventures, to support the company’s rapid growth and global expansion. Other investors participating from previous rounds include Pitango Venture Capital, 7wire ventures, lool Ventures, TriVentures and Qualcomm Ventures.

2017/02/24
Storm Therapeutics appoints CEO and Chairman

CAMBRIDGE, UK (24 FEB 2017) - Storm Therapeutics, the drug discovery company focused on the discovery of small molecule therapies from RNA epigenetics, moved to the next stage of its development with the appointment of Keith Blundy as Chief Executive Officer and Tim Edwards as Chairman.

2017/02/20
New Data Demonstrate Significant Expansion of Therapeutic Index vs Cysteine-Engineered ADCs

AMSTERDAM, NETHERLANDS – February 20, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.

2017/02/08
Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic

**Forbion & Seroba co-led funding, forming international consortium of M Ventures, Ysios and Sunstone Funding to finance two Phase II trials in Parkinson’s disease** **Geneva, Switzerland and Amsterdam, The Netherlands, February 7, 2017** - Prexton Therapeutics (Prexton), a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, today announces the closing of a Series B financing round of €29 million ($31M).

2017/01/26
ObsEva SA Announces Pricing of Initial Public Offering

Geneva, Switzerland - January 25, 2017 - ObsEva SA (ObsEva) announced today the pricing of its initial public offering of 6,450,000 common shares at the initial public offering price of $15.00 per share. In addition, ObsEva has granted the underwriters an option to purchase up to 967,500 additional common shares to cover over-allotments. The offering is expected to close on or about January 31, 2017, subject to customary closing conditions. ObsEva's common shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol "OBSV" on January 26, 2017. Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the proposed offering.

2017/01/05
ARTSaVIT Ltd. Completes $6.3 Million Series A Financing

YAVNE, Israel, January 5, 2016 - Israeli cancer apoptosis company ARTSaVIT LTD announced today that it has completed a $6.3 million Series A round of financing led by Arkin Bio Ventures and Pontifax, with participation of M Ventures, Carmel Innovation and Carmel - Haifa University Economic Corporation Ltd.